SEC filings and other documents

Q1 2026 revenue surged 104% year-over-year, with strong margins and expanded payer coverage.

TULSA-PRO delivers safer, faster prostate ablation with strong clinical and market momentum.

AI-powered, incision-free prostate therapy drives growth with strong data and expanding coverage.

TULSA-PRO offers safer, faster, and more profitable prostate treatment with strong clinical backing.

TULSA outperforms surgery in safety, recovery, and function, advancing toward guideline inclusion.

Q4 revenue up 43% year-over-year, with strong TULSA-PRO adoption and improving margins.

MRI-guided, AI-driven platforms are transforming non-invasive prostate and gynecological care.

Q3 revenue up 87% year-over-year, gross margin at 74.3%, and strong commercial growth.

Rapid TULSA-PRO adoption, strong clinical data, and expanding reimbursement fuel growth.

Q2 revenue steady, gross margin up, net loss widened; strong pipeline supports 2025 growth.

Q1 revenue up 82% year-over-year; strong clinical data and new AI modules drive growth outlook.

TULSA delivers MRI-guided, incision-free prostate ablation with superior outcomes and broad reimbursement.

TULSA achieves superior outcomes and rapid adoption, driven by innovation and strong patient demand.

AI-driven MRI therapy for prostate and BPH accelerates growth, with new modules and markets ahead.

Record Q4 revenue and margin, improved net loss, and strong growth outlook for 2025-26.

CMS Level 7 reimbursement and AI-driven TULSA-PRO set the stage for rapid market expansion.